Bioline RX

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. Its pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is a immunotherapy treatment used fro multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

New York, New York--(Newsfile Corp. - January 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd. (NASDAQ: BLRX) resulting from allegations that BioLineRx may have issued materially misleading business information to the investing public.

BLRX NOTICE: ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation - BLRX

NEW YORK , Dec. 30, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd. (NASDAQ: BLRX) resulting from allegations that BioLineRx may have issued materially misleading business information to the investing public.

BLRX SHAREHOLDER ALERT: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation - BLRX

NEW YORK--( BUSINESS WIRE )--WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd. (NASDAQ: BLRX) resulting from allegations that BioLineRx may have issued materially misleading business information to the investing public.

TOP RANKED ROSEN LAW FIRM Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

Study Met Primary Endpoint for Safety and Tolerability First-in-Human, Single-Agent Study Demonstrated Immune Activity Across Multiple Biomarkers Company to Seek Publication of Complete Data Analysis in 2023  TEL AVIV, Israel , Dec. 20, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from the Phase 1/2a study of intratumoral cancer vaccine candidate, AGI-134, designed to evaluate the safety and biological activity of AGI-134 in patients with unresectable metastatic solid tumors.

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

TEL AVIV, Israel , Nov. 28, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that management will participate in the 12th Annual LifeSci Partners Corporate Access Event, taking place January 9-11, 2023, in San Francisco, CA, and will be available for one-one-one meetings on January 11, 2023.

BioLineRx to Participate in the 12th Annual LifeSci Partners Corporate Access Event

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2022 Earnings Conference Call November 15, 2022 10:00 AM ET Company Participants John Lacey - IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Abi Vainstein-Haras - Chief Medical Officer Conference Call Participants Joe Pantginis - H.C.

BioLineRx Ltd. (BLRX) Q3 2022 Earnings Call Transcript

- Announced FDA acceptance of APHEXDA® (motixafortide) New Drug Application (NDA) in stem cell mobilization with Prescription Drug User Fee Act (PDUFA) target action date of September 9, 2023 - - Introduced plan to commercialize APHEXDA® independently in the U.S., if approved, and named Holly May, President, BioLineRx USA  - - Completed $40M debt financing agreement and $15M equity offering to support aggressive commercial U.S. launch of APHEXDA® -  - Management to hold conference call today, November 15, at 10:00 am EST - TEL AVIV, Israel , Nov. 15, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reported third quarter financial results and recent corporate and portfolio updates.

BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates

TEL AVIV, Israel, Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended September 30, 2022 on Tuesday, November 15, 2022, before the U.S. markets open.

BioLineRx to Report Third Quarter 2022 Results on November 15, 2022

- PDUFA target action date set for September 9, 2023 - NDA submission based on GENESIS Phase 3 trial data that met all primary and secondary endpoints with a high level of statistical significance - Company advancing preparations for robust commercial launch TEL AVIV, Israel , Nov. 10, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed the Company's New Drug Application (NDA) for APHEXDA® (motixafortide) in stem cell mobilization for autologous transplantation in multiple myeloma patients.

BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization

Full data from pharmacoeconomic study will be presented demonstrating significant cost benefits from using motixafortide in combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation  Phase 1 trial design of novel hematopoietic stem cell mobilization regimen including motixafortide for gene therapy in patients with sickle cell disease to be presented; a potential new development area  TEL AVIV, Israel , Nov. 3, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that its full pharmacoeconomic study that indirectly evaluated the cost-effectiveness of using the investigational drug motixafortide as a primary stem cell mobilization (SCM) agent in combination with granulocyte colony stimulating factor (G-CSF), against plerixafor in combination with G-CSF, in multiple myeloma (MM) patients undergoing autologous stem cell transplantation, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting held from December 10-13 in New Orleans, LA.

BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting

Company to accelerate availability to patients and maximize value through independent commercialization to well-defined U.S. transplant center community Veteran product launch leader Holly May named President, BioLineRx USA Company introduces APHEXDA as Motixafortide's FDA approved trade name Company to host Investor and Key Opinion Leader webinar TOMORROW, Wednesday, September 28, at 9:00 a.m. EDT  TEL AVIV, Israel , Sept.

BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization

NEW YORK , Sept. 22, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd.

BLRX INVESTOR ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation - BLRX

Los Angeles, California--(Newsfile Corp. - September 20, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioLineRx Ltd. ("BioLineRx" or "the Company") (NASDAQ: BLRX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $BLRX #BLRX--The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - September 19, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BioLineRx Ltd. ("BioLineRx" or "the Company") (NASDAQ: BLRX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential civil securities claims on behalf of shareholders of BioLineRx Ltd. (NASDAQ: BLRX). SO WHAT: If you purchased BioLineRx securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospe

EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX

TEL AVIV, Israel , Sept. 19, 2022 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Announces $15 Million Registered Direct Offering

Funds to be used to support aggressive commercial launch in the US for Motixafortide in stem cell mobilization, if approved TEL AVIV, Israel , Sept. 15, 2022 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital

Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 study  Stem cell mobilization for bone marrow transplantation estimated to be > $360 million market in the U.S. ( > $500 million globally), with consistent growth  TEL AVIV, Israel , Sept. 12, 2022 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2022 Earnings Conference Call August 16, 2022 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Holly May - Chief Commercial Officer Conference Call Participants Joe Pantginis - H.C.

BioLineRx Ltd. (BLRX) CEO Philip Serlin on Q2 2022 Results - Earnings Call Transcript

- Submission of New Drug Application to FDA for Motixafortide in stem cell mobilization (SCM) for autologous stem cell transplantation expected within next 4-6 weeks - - Announced appointment of commercial strategy and operations veteran Holly May as U.S.-based Chief Commercial Officer - - Entered into collaboration agreement with GenFleet Therapeutics to advance Motixafortide in pancreatic cancer (PDAC) - - Management to hold conference call today, August 16, at 10: 00 am EDT - TEL AVIV, Israel , Aug. 16, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today reports its financial results for the second quarter ended June 30, 2022 and provides a corporate update.

BioLineRx Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Management to hold a conference call at 10:00 a.m. EDT TEL AVIV, Israel , Aug. 11, 2022 /PRNewswire/ -- BioLineRx Ltd.

BioLineRx to Report Second Quarter 2022 Results on August 16, 2022

NEW YORK , June 29, 2022 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd.

BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures

- GenFleet to design and execute randomized Phase 2b triple combination trial of Motixafortide in first-line metastatic PDAC patients in China - - BioLineRx to retain global rights to Motixafortide in all indications - -Collaboration based on positive final results from Phase 2a COMBAT/KEYNOTE-202 study of Motixafortide in combination with anti-PD-1 and chemotherapy as second-line metastatic PDAC therapy - TEL AVIV, Israel , June 28, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that the Company has entered into a collaboration agreement with GenFleet Therapeutics, an immuno-oncology focused biopharmaceutical company based in China, to advance Motixafortide through a randomized Phase 2b clinical trial in pancreatic ductal adenocarcinoma, or PDAC.

News for Bioline RX Stock (BLRX)